Insights
Insights From Our Experts
Articles
M&A and BD&L Outlook and Perspectives on Commercial Due Diligence
In this webinar, industry leaders Faruk Abdullah, Jakub Pijewski, PhD, and Yao Zhang, PhD, delve into the dynamic world of M&A, BD&L, and Commercial Due Diligence (CDD) in the pharmaceutical and biotech sectors. Gain valuable insights into:…
Optimizing Patient-Centered Care: Strategies for Improving Health Outcomes
With a rapidly evolving health insurance landscape in India, it is imperative to understand the challenges and potential solutions for innovative medical technologies reimbursement by private health insurance in India. EVERSANA recently partnered with St. Jude…
Bridging “Share of Voice” with “Share of Influence” for Lasting Impact
In today’s complex healthcare environment, manufacturers must navigate an evolving stakeholder landscape to guarantee patient access and successful product launches. This article explores how deploying a strategic approach that establishes a “share of influence” across the…
Celebrating Excellence: Two EVERSANA Leaders Named to PM360 Elite 100 List
We’re excited to share that two EVERSANA leaders have been recognized in the prestigious 2024 PM360 ELITE 100 List. PM360 ELITE celebrates individuals who exemplify excellence and innovation in the healthcare industry. Highlighted among this year’s…
Integrated Delivery Networks (IDNs): Driving Change in Drug Access and Utilization
As of May 2024, a striking 77.6% of physicians in the United States are employed by hospitals, health systems and corporate entities – a significant surge from less than 50% a mere decade ago. This trend…
Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC
Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques,…
Demystifying the New Prescription Drug Use-Related Software Framework
Authors: Kory Dillman and Scott Kellogg The Food and Drug Administration (FDA) unveiled its draft guidance on Regulatory Considerations for Prescription Drug Use-Related Software (PDURS) in September 2023. The document shed light on how the FDA intended…
Price Right or Pay Later
Dive into the intricate world of pharmaceutical pricing with “Price Right or Pay Later” by Chad McAuliffe, and Andrew Therrien. In this groundbreaking paper, EVERSANA exposes the critical yet often overlooked nuances of pricing strategies in…
Leveraging Generative AI in Brand Planning: Insights from Second Annual Pharmaceutical Brand Planning Survey
Discover the cutting-edge insights from EVERSANA’s second annual Pharmaceutical Brand Planning Survey. Dive into the burgeoning trend of integrating generative AI into brand planning within the life sciences sector. This comprehensive report, based on responses from…
Maximizing Sales Impact in a Hybrid World
In an evolving pharmaceutical landscape, traditional sales methods are giving way to a new hybrid approach. “Maximizing Sales Impact in a Hybrid World” delves into this transformative shift, exploring how data-driven strategies blend personal and non-personal…